Journal Mobile Options
Table of Contents
Vol. 16, No. 6, 1998
Issue release date: November–December 1998
Blood Purif 1998;16:341–348
(DOI:10.1159/000014354)

Long-Term Extracorporeal Bilirubin Elimination: A Case Report on Cascade Resin Plasmaperfusion

Mertens P.R. · Schönfelder T. · Handt S. · Kierdorf H. · Marschall H.-U. · Busch N. · Heintz B. · Sieberth H.-G.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Acute hepatic failure develops as a disease entity of rather diverse origin. With disease progression, toxic bilirubin levels may cause severe complications which include AV-nodal blockage, cardiac arrhythmia, impaired consciousness, generalized seizures, and status epilepticus. Treatment choices to prevent clinical deterioration comprise of costly and limited available orthotopic liver transplantation, utilization of extracorporeal bioartificial liver support devices and haemoperfusion/plasmaperfusion treatment with activated charcoal/anion exchange filters. Here, we present a patient with acute drug-induced cholestatic hepatitis. Excessively elevated bilirubin levels were accompanied by cardiac and cerebral complications. Extracorporeal resin perfusion treatment (Plasorba, BR–350) was successfully performed over a 50-day period without activation of the coagulation system or side effects. Bilirubin levels were lowered to a minimum of 225 μmol/l, with concurrent clinical improvement. In conclusion, extracorporeal anion exchange plasmaperfusion may be a viable long-term treatment for hyperbilirubinaemic side effects in overt cholestatic hepatitis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Miller D, Keeton G, Webber B, Saunders S: Jaundice in severe bacterial infections. Gastroenterology 1976;71:1799–1805.
  2. Green RM, Beier D, Gollan JL: Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 1996;111:193–198.
  3. Green RM, Whiting JF, Rosenbluth AB, Beier D, Gollan JL: Interleukin–6 inhibits hepatocyte taurocholate uptake and sodium-potassium-adenosinetriphosphatase activity. Am J Physiol 1994;267:G1094-G1100.

    External Resources

  4. Dawson JL: Acute postoperative renal failure in obstructive jaundice. Ann R Coll Surg Engl 1968;42:163–170.

    External Resources

  5. Kew MC, Brunt PW, Varma RR, Hourigan KJ, Williams HS, Sherlock S: Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971;2:504–510.

    External Resources

  6. Papper S: Hepatorenal syndrome; in Epstein M (ed): The Kidney in Liver Disease, ed 2. New York, Elsevier Biomedical, 1983, pp 87–106.
  7. Cowger ML, Labbe RF: Bilirubin toxicity in cultured mammalian cells. Fed Proc 1964;23:233–238.
  8. Wiessman G: Studies of lysosomes. IV. The effect of neutral steroids and bile acids on lysosomes in vitro. Biochem Pharmacol 1965;14:525–529.

    External Resources

  9. O’Grady JG, Alexander GJ, Hayllar KM, Williams R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439–445.
  10. Ascher NL, Lake JR, Emond JC: Liver transplantation for fulminant hepatic failure. Arch Surg 1993;128:677–682.
  11. Kong LB, Chen S, Demetriou AA, Rozga J: Matrix-induced liver cell aggregates for bioartificial liver use. Int J Artif Organs 1996;19:72–78.
  12. Rozga J, Demetriou AA: Artificial liver. Evolution and future perspectives. ASAIO J 1995;41:831–837.
  13. Gerlach JC: Development of a hybrid liver support system: A review. Int J Artif Organs 1996;19:645–654.
  14. O’Grady JG, Gimson AES, O’Brien CJ, Pucknell A, Hughes RD, Williams R: Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94:1186–1192.
  15. Suenaga M, Yoshikatsu O, Sugiura H, Kokuba Y, Uehara S, Mori K, Yamaguchi S, Yamanaka N, Oda O: Effect of therapeutic plasma exchange and bilirubin adsorption on serum bilirubin subfractions in hepatic failure. Ther Plasmapher 1993;12:175–179.
  16. Geiger H, Klepper J, Lux P, Heidland A: Biochemical assessment and clinical evaluation of a bilirubin adsorbent column (BR–350) in critically ill patients with intractable jaundice. Int J Artif Organs 1992;5:35–39.
  17. Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA, Williams R: Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs 1994;17:657–662.
  18. Lee MG, Hanchard B, Williams NP: Drug-induced acute liver disease. Postgrad Med J 1989;65:367–370.

    External Resources

  19. Jochem V, Kirkpatrick R, Greenson J, Brogan M, Sturgis T, Cook-Glenn C: Fulminant hepatic failure related to omeprazole. Am J Gastroenterol 1992;87:523–525.
  20. Hautekeete ML: Hepatotoxicity of antibiotics. Acta Gastroenterol Belg 1995;58:290–296.

    External Resources

  21. Neuberger J: Drug-induced jaundice. Gastroenterology 1989;3:447–466.
  22. Kaplowitz N, Aw TY, Simon FR, Stolz A: Drug-induced hepatotoxicity. Ann Intern Med 1984;104:826–839.
  23. Vial T, Goubier C, Bergeret A, Cabrera F, Evreux JC, Descotes J: Side effects of ranitidine. Drug Saf 1991;6:94–117.
  24. Lienart F, Morissens M, Jacobs P, Ducobu J: Doxycycline and hepatotoxicity. Acta Clin Belg 1992;47:205–208.
  25. Gholson CF, Warren GH: Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990;150:215–216.
  26. Makowka L, Cramer DV, Hoffman A, Breda M, Sher L, Eiras-Hreha G, Tuso PJ, Yasunaga C, Cosenza CA, Cosenza CA, Wu GD, Chapman FA, Podesta L: The use of a pig liver xenograft for temporary support of a patient with fulminant hepatic failure. Transplantation 1995;59:1654–1659.
  27. Nyberg SL, Peshwa MV, Payne WD, Hu WS, Cerra FB: Evolution of the bioartificial liver: The need for randomized clinical trials. Am J Surg 1993;166:512–521.
  28. Nyberg SL, Misra SP: Hepatocyte liver-assist systems – A clinical update. Mayo Clin Proc 1998;73:765–771.
  29. Matthew HW, Basu S, Peterson WD, Salley SO, Klein MD: Performance of plasma-perfused, microencapsulated hepatocytes: prospects for extracorporeal liver support. J Pediatr Surg 1993;28:1423–1427.
  30. Rozga JR, Holzman MD, Ro M-S, Griffin DW, Neuzil DF, Giorgio T, Moscioni AD, Demetriou AA: Development of a hybrid bioartificial liver. Annals Surg 1993;217:502–511.
  31. Gerlach J, Encke J, Hole O, Muller C, Courtney J, Neuhaus P: Hepatocyte culture between three dimensional arranged biomatrix-coated independent artificial capillary systems and sinusoidal endothelial cell coculture compartments. Int J Artif Organs 1994;17:301–306.
  32. Sussmann NL, Gislason G, Conlin CA, Kelly JH: The Hepatix extracorporeal liver assist device: Initial clinical experience. Artif Organs 1994;18:390–396.
  33. Catapano G: Mass transfer limitations to the performance of membrane bioartificial liver support devices. Int J Artif Organs 1996;19:18–35.
  34. Rozga J, Podesta L, LePage E, Morisani E, Moscioni AD, Hoffman A, Sher L, Villamil F, Woolf G, McGrath M, Kong L, Rosen H, Lanman T, Vierling J, Makowka L, Demetriou AA: A bioartificial liver to treat severe acute liver failure. Ann Surg 1994;5:538–546.
  35. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, Gislason GT, Sussman NL, Williams R: Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24:1446–1451.
  36. Watanabe FD, Mullon CJ, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, Khalili T, Arnaout W, Shackleton CR, Rozga J, Sobmon B, Demetriou AA: Clinical experience with a bioartificial liver in the treatment of severe liver failure: A phase I clinical trial. Ann Surg 1997;225:484–491.
  37. Wu TW: Bilirubin analysis – state of the art and future prospects. Clin Biochem 1984;17:221–229.

    External Resources

  38. Schiff L, Schiff ER: Diseases of the Liver, ed 7. Philadelphia, Lippincott, 1993.
  39. Davenport A, Will EJ, Davison AM: Adverse effects on cerebral perfusion of prostacyclin administered directly into patients with fulminant hepatic failure and acute renal failure. Nephron 1991;59:449–454.
  40. Hawker F: Liver dysfunction in critical illness. Anaesth Intensive Care 1991;19:165–181.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50